Personal CFO Solutions LLC Takes Position in Exact Sciences Co. (NASDAQ:EXAS)

Personal CFO Solutions LLC acquired a new stake in shares of Exact Sciences Co. (NASDAQ:EXAS) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 2,411 shares of the medical research company’s stock, valued at approximately $226,000.

Several other large investors also recently made changes to their positions in EXAS. Norges Bank bought a new position in shares of Exact Sciences during the 4th quarter valued at about $47,037,000. Artisan Partners Limited Partnership boosted its holdings in shares of Exact Sciences by 31.8% in the second quarter. Artisan Partners Limited Partnership now owns 3,542,744 shares of the medical research company’s stock worth $332,664,000 after buying an additional 855,418 shares during the period. Capital World Investors boosted its holdings in shares of Exact Sciences by 17.2% in the first quarter. Capital World Investors now owns 5,487,009 shares of the medical research company’s stock worth $383,652,000 after buying an additional 804,159 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Exact Sciences by 4.4% in the third quarter. Vanguard Group Inc. now owns 16,676,611 shares of the medical research company’s stock worth $541,823,000 after buying an additional 698,740 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Exact Sciences by 68.1% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,532,063 shares of the medical research company’s stock worth $143,861,000 after buying an additional 620,592 shares during the period. Institutional investors own 89.13% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on EXAS. The Goldman Sachs Group decreased their target price on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating for the company in a report on Friday, November 3rd. Robert W. Baird raised their price target on shares of Exact Sciences from $99.00 to $121.00 and gave the stock an “outperform” rating in a report on Wednesday, August 2nd. Piper Sandler decreased their price target on shares of Exact Sciences from $90.00 to $80.00 and set an “overweight” rating for the company in a report on Monday, October 16th. Jefferies Financial Group raised their price target on shares of Exact Sciences from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, Bank of America raised their price target on shares of Exact Sciences from $105.00 to $110.00 in a report on Wednesday, August 2nd. Five research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $96.56.

Exact Sciences Trading Up 1.5 %

NASDAQ:EXAS opened at $67.29 on Tuesday. Exact Sciences Co. has a 12 month low of $40.73 and a 12 month high of $100.77. The firm has a market cap of $12.17 billion, a price-to-earnings ratio of -42.32 and a beta of 1.46. The company has a quick ratio of 2.13, a current ratio of 2.41 and a debt-to-equity ratio of 0.74. The company’s 50 day moving average is $66.20 and its 200-day moving average is $79.81.

Insider Transactions at Exact Sciences

In other news, insider Everett Cunningham sold 13,007 shares of the firm’s stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $66.49, for a total value of $864,835.43. Following the sale, the insider now owns 37,909 shares in the company, valued at $2,520,569.41. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.